Uzbekistan Digital Health Platform - Integrations
0.12.1 - draft Uzbekistan флаг

This page is part of the Uzbekistan Digital Health Platform - Integrations (v0.12.1: Releases Draft) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version. For a full list of available versions, see the Directory of published versions

6.0 Genetics & Screening

Для текущей страницы не существует страницы перевода, поэтому онаотображается на языке по умолчанию

Volume 6 covers the "mother and child" screening programme: checking an unborn baby for serious conditions during pregnancy, and checking a newborn in its first days of life. It is run in dedicated screening centres and is closely tied to ordinary pregnancy care in volume 2 and the birth itself in volume 1.

What screening involves

Screening means testing people who seem healthy to catch hidden problems early. This volume has two distinct halves, joined by the birth:

  • Before birth (prenatal). During pregnancy, the mother has ultrasound scans and blood tests at set points (the "trimesters"). These do not give a diagnosis; they estimate the chance that the baby has a condition such as Down syndrome. If that chance is high, the mother is offered a more definitive but more invasive test, where a sample is taken from the womb and the baby's chromosomes are examined directly. Because that test carries a small risk to the pregnancy, the mother must give informed consent, and she is free to decline.
  • After birth (neonatal). In the first days of life the baby's heel is pricked for a few drops of blood, which are tested for a handful of rare but treatable conditions. If a result is abnormal, the baby is re-tested and investigated further before anything is concluded.

The important idea for a non-expert is that screening is a funnel: many people are screened, a few are flagged, and only those few go on to the definitive tests. The forms follow that funnel.

How the forms relate

The prenatal track is a decision chain. The exam card (159) opens the file. The trimester ultrasound (162-164) and biochemical screening (156-157) produce a risk estimate. A high risk leads to a counselling step where the mother either consents (152, 153) or refuses (155). Consent unlocks the invasive procedure (166), which produces a cytogenetic result (154), which feeds the genetic conclusion (165, 172) and, in difficult cases, a panel discussion called a perinatal consilium (173). Each step gates the next, so the forms are genuinely sequential.

The neonatal track is a shorter chain: the heel-prick screen (167) leads, only if abnormal, to confirmatory tests (168, 170) and a retest (171).

A third small group is the registry for people already known to have a hereditary disease (158) and their specialist check-ups (160, 161).

The diagram shows the two tracks and the consent gate between screening and the invasive test:

Volume 6 - prenatal and neonatal tracks, coloured by document typePrenatal (mother)Neonatal (baby)Hereditary-disease registry«card»159 Prenatalexam card«report»162-164 Trimesterultrasound protocols«conclusion»156-157 Biochemicalscreening conclusions«consent»152/153 Informedconsent«consent»155 Refusal ofinvasive diagnosis«report»166 Invasivediagnosis procedure«report»154 Cytogenetic /molecular result«conclusion»165/172 Geneticconclusion«conclusion»173 Perinatalconsilium«report»167 Neonatalscreening«report»168/170 Tandem MS /sweat test«report»171 Retest«card»158 Genetic-patientambulatory card«card»160/161 Specialistconsult cardsif riskblocksBlue = longitudinal cardGreen = reportYellow = consent / refusal statementPurple = conclusion


A sample pathway

Imagine a woman early in pregnancy, referred from her polyclinic (037-1) to the screening centre, where an exam card is opened (159). Her first-trimester ultrasound (162) and blood screen (156) come back showing an increased chance of a chromosomal condition. A counsellor explains the options, and she decides to go ahead with the definitive test, signing a consent form (152). The procedure is done (166) and the laboratory examines the baby's chromosomes (154). The result is discussed by a panel (173) and a genetic conclusion is issued (165). Months later, after a healthy birth, the newborn has the routine heel-prick screen (167), which is normal, and no further action is needed.

The sequence below traces that pathway, including the point where a mother might decline:

Sample flow - prenatal screening and the invasive-diagnosis decisionPregnantwomanPregnantwomanPolyclinic(vol 2)Polyclinic(vol 2)Screening centre(vol 6)Screening centre(vol 6)Newborn(vol 6)Newborn(vol 6)1037-1 prenatal referral2159 prenatal exam card3162-164 trimester ultrasound protocols156-157 biochemical screening conclusionsalt[screening shows increased risk]4counsellingalt[woman consents]5152 / 153 informed consent6166 invasive prenatal diagnosis procedure154 cytogenetic / molecular result7165 genetic conclusion, 172 post-procedure conclusion173 perinatal consilium[woman declines]8155 refusal of invasive diagnosisafter birth9heel-prick sample10167 neonatal screening (IRT, PKU, CH)alt[abnormal]11168 tandem mass-spec / 170 sweat test / 171 retest


This is the screening portion of the wider maternity journey that also spans volumes 2 and 1.

Forms in this volume

Form Title Type
152, 153 Informed consent for invasive prenatal diagnosis Consent
154 Cytogenetic / molecular-cytogenetic result Report
155 Refusal of invasive prenatal diagnosis Statement
156, 157 First / second trimester biochemical screening conclusion Conclusion
158 Hereditary-genetic patient ambulatory card Card
159 Pregnant woman prenatal examination card Card
160, 161 Genetic patient consults (neuropathologist, endocrinologist) Card
162, 163, 164 First / second / third trimester ultrasound screening protocol Report
165 Medical genetic conclusion Conclusion
166 Invasive prenatal diagnosis procedure protocol Report
167 Neonatal screening (IRT, PKU, congenital hypothyroidism) Analysis
168 Tandem mass-spectrometry analysis Analysis
169 Clinical-diagnostic laboratory IXLA analysis Analysis
170 Sweat test Analysis
171 Neonatal retest screening Analysis
172 Post-invasive-diagnosis conclusion Conclusion
173 Perinatal consilium Conclusion
174 Pre-surgery epicrisis for a pregnant woman Epicrisis